Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study
Author(s) -
Antonio Ocampo,
Peré Domingo,
Pedro L. Fernández,
Julio Diz,
José Ramón Barberá,
Marcela Sepúlveda,
X Salgado,
Miguel Ángel Palomero Rodríguez,
Jesús Santos,
Miguel Yzusqui,
Marisa Mayorga,
Javier Fernández Lorenzo,
Alberto Bahamonde,
P Bachiller,
Elisa Martínez,
Nerea Rozas,
Carolina Machado Torres,
Álvaro Muñoz,
Araceli Casado,
Daniel Podzamczer
Publication year - 2018
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dky175
Subject(s) - tolerability , emtricitabine , rilpivirine , medicine , ritonavir , efavirenz , lamivudine , gastroenterology , prospective cohort study , cohort , viral load , human immunodeficiency virus (hiv) , adverse effect , antiretroviral therapy , virology , virus , chronic hepatitis
To analyse lipid changes and tolerability in a cohort of HIV-infected patients who switched their antiretroviral regimens to rilpivirine/emtricitabine/tenofovir (RPV/FTC/TDF) in a real-world setting.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom